Synthetic Biology

AgriTech
Bioprocessing
Pharmaceuticals
Proteomics
Synthetic Biology

Multiply Labs is revolutionizing cell therapy production with ai

Multiply Labs is revolutionizing cell therapy production with robotic systems and AI-driven digital twins.

Multiply Labs is revolutionizing cell therapy production with robotic systems and AI-driven digital twins, cutting costs by up to 70%, increasing throughput, and reducing contamination ri

The Biotech Times Editorial Team  · 
Synthetic Biology
AgriTech

Fieldstone Bio joins Rio Tinto mining accelerator

The synthetic biology startup will work with Rio Tinto's geologists to commercialise biosensor-based critical-mineral measurement for exploration teams.
The synthetic biology startup will work with Rio Tinto's geologists to commercialise biosensor-based critical-mineral measurement for exploration teams.
The Biotech Times Editorial Team  · 
Biologics
Synthetic Biology
Bioprocessing

NorthStrive Biosciences engages Charles River for probiotic CRO work

NorthStrive Biosciences has signed a statement of work with Charles River Laboratories to characterise plasmid copy numbers in its EL-22 and EL-32 engineered
NorthStrive Biosciences has signed a statement of work with Charles River Laboratories to characterise plasmid copy numbers in its EL-22 and EL-32 engineered
The Biotech Times Editorial Team  · 
AgriTech
Synthetic Biology

Cibus and Crystal Crop partner to gene-edit India's mustard crop

The deal gives Crystal Crop exclusive India rights to Cibus gene-editing technology targeting higher mustard yields across 8.5 million hectares.
The deal gives Crystal Crop exclusive India rights to Cibus gene-editing technology targeting higher mustard yields across 8.5 million hectares.
The Biotech Times Editorial Team  · 
Synthetic Biology
Bioprocessing

Kraig Biocraft completes Atlas Gene Library in silkworm hosts

Kraig Biocraft says finishing its Atlas Gene Library unlocks over 200 genetic configurations in its pursuit of advanced spider silk fibres.
Kraig Biocraft says finishing its Atlas Gene Library unlocks over 200 genetic configurations in its pursuit of advanced spider silk fibres.
The Biotech Times Editorial Team  · 
Biologics
Synthetic Biology
Cell & Gene Therapy

Scarlet Therapeutics wins $14m DARPA deal for smart red blood cells

The Bristol biotech will lead an international consortium to engineer red blood cells that sense and respond to physiological changes.
The Bristol biotech will lead an international consortium to engineer red blood cells that sense and respond to physiological changes.
The Biotech Times Editorial Team  · 
Bioprocessing
Synthetic Biology

CBAK Energy completes Nanjing Phase II ramp-up amid $96m India order

The Chinese battery maker says Model 32140 shipments doubled year-on-year as it targets India's fast-growing light electric vehicle market.
The Chinese battery maker says Model 32140 shipments doubled year-on-year as it targets India's fast-growing light electric vehicle market.
The Biotech Times Editorial Team  · 
Bioprocessing
Synthetic Biology

Capra Biosciences secures more HHS funding to onshore API output

Total ASPR backing reaches $17m as the Virginia biotech moves seven API targets toward commercial-scale domestic manufacturing.
Total ASPR backing reaches $17m as the Virginia biotech moves seven API targets toward commercial-scale domestic manufacturing.
The Biotech Times Editorial Team  · 
Synthetic Biology

Amber Implants expands EXPAND study of VCFix to eight European centres

The Dutch medtech has enrolled 15 patients and expanded its pivotal vertebral reconstruction trial across Germany and France.
The Dutch medtech has enrolled 15 patients and expanded its pivotal vertebral reconstruction trial across Germany and France.
The Biotech Times Editorial Team  · 
Synthetic Biology
Biotech

Celldex CDX-622 shows durable mast cell depletion in Phase 1 data

First-in-human results for the bispecific antibody showed rapid, dose-dependent serum tryptase reductions and a clean safety profile across all dose levels.
First-in-human results for the bispecific antibody showed rapid, dose-dependent serum tryptase reductions and a clean safety profile across all dose levels.
The Biotech Times Editorial Team  · 
Synthetic Biology

Genmab epcoritamab shows high response rates in elderly DLBCL patients

Phase 2 data presented at EHA 2026 show epcoritamab monotherapy and a combination regimen achieved strong complete response rates in first-line elderly DLBCL patients.
Phase 2 data presented at EHA 2026 show epcoritamab monotherapy and a combination regimen achieved strong complete response rates in first-line elderly DLBCL patients.
The Biotech Times Editorial Team  · 
Bioprocessing
Synthetic Biology
Biotech

AMG Critical Materials beats Q1 2026 guidance on vanadium strength

AMG Critical Materials posted $44m adjusted EBITDA in Q1 2026, ahead of guidance, driven by vanadium gains and the AURA acquisition.
AMG Critical Materials posted $44m adjusted EBITDA in Q1 2026, ahead of guidance, driven by vanadium gains and the AURA acquisition.
The Biotech Times Editorial Team  · 
Subscribe to Synthetic Biology